智能胰岛素与智能胰岛素对比 1型糖尿病的人工智能:真正的赢家请站起来吗?
Valentina Maria Cambuli1, Marco Giorgio Baroni2,3
1Diabetology and Metabolic Diseaseas, San Michele Hospital, ARNAS Giuseppe Brotzu, 09121 Cagliari, Italy.
International journal of molecular sciences
|September 9, 2023
概括
智能胰岛素和人工智能 (AI) 正在推进1型糖尿病治疗. 人工智能驱动的系统正在接近完全自动化的人工胰腺的创建,以改善血糖控制.
科学领域:
- 生物医学工程 生物医学工程
- 内分泌学 在内分泌学.
- 人工智能的人工智能
背景情况:
- 1型糖尿病的管理传统上依赖于外部胰岛素的输送.
- 目前的研究重点是自主葡萄糖调节系统.
- 现有的治疗方法需要不断监测和干预患者.
研究的目的:
- 审查1型糖尿病的"智能胰岛素"的进展.
- 探索人工智能 (AI) 在自动化胰岛素治疗中的应用.
- 概述这些技术的现状和未来潜力.
主要方法:
- 关于智能胰岛素的最新科学文献的综述.
- 对利用人工智能用于胰岛素治疗决策支持的研究进行分析.
- 关于自动注射胰岛素和血糖控制的发现综合.
主要成果:
- "智能胰岛素"正在开发,用于基于葡萄糖水平的自我调节.
- 人工智能在改进自动化胰岛素输送系统方面显示出显著的前景.
- 研究正在向一个"闭环"的人工胰腺系统取得进展.
结论:
- 人工智能和智能胰岛素的整合为1型糖尿病管理提供了有希望的未来.
- 由AI指导的自动胰岛素治疗显著提高了血糖控制.
- 功能性人工胰腺的开发正在接近实现.
相关概念视频
Diabetes Mellitus: Overview and Type I Subtype
2.7K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.7K
Insulin: Dosing Regimen and Adverse Effects
205
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
205
Insulin Formulations: Types and Delivery
225
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
225
Insulin: Biosynthesis, Chemistry, and Preparation
422
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
422
Diabetes: Management and Pharmacotherapy
309
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
309
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.3K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.3K


